UTHR News and Press, United Therapeutics Corporation From 08/24/22

Summary Tyvaso is being explored by United Therapeutics Corporation in the TETON program (two phase 3 studies) which will determine if label expansion for idiopathic pulmonary fibrosis can be achieved. Tyvaso in an ad-hoc analysis in the short 16-week INCREASE study was shown to i...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four posters and one oral presentation will be presented at the European Society of Cardiology ( ESC ) Congress 2022, taking place August 26-29, 2022, and the European Respiratory Soci...

Toast ( NYSE: TOST ) jumped in Friday's midday trading, boosted by quarterly results that exceeded analysts' projections. Liquidia ( LQDA ) represented another intraday standout, surging on developments in a patent case. Elsewhere, new IPO Forza X1 ( FRZA ) more than dou...

Liquidia Corp. ( NASDAQ: LQDA ) rose 8.6% after a judge issued an order suggesting that 793 patent should be considered invalid. The judge indicated that the Liquidia ( LQDA ) filed a notice with PTAB that invalidated all claims of the 793 patent. Recall LQDA ...

In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill them. Simply put, it means failing to start or intensify a therapy when appropriate, which leads to advanced or chronic disea...

United Therapeutics Corporation (UTHR) Q2 2022 Results Conference Call August 3, 2022 09:00 AM ET Company Participants Dewey Steadman - Head, IR Dr. Martine Rothblatt - Chairperson, CEO Michael Benkowitz - President, COO Dr. Leigh Peterson - SVP, Product Deve...

United Therapeutics press release ( NASDAQ: UTHR ): Q2 GAAP EPS of $2.41 misses by $1.55 . Revenue of $466.9M (+4.6% Y/Y) beats by $5.84M . “The recent approval and launch of Tyvaso DPI, coupled with the Medicare coverage decision for Tyvaso in PH-ILD, w...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared to $446.5 million in the second quarte...

United Therapeutics ( NASDAQ: UTHR ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, before market open. The consensus EPS Estimate is $4.54 (+11.0% Y/Y) and the consensus Revenue Estimate is $461.06M (+3.3% Y/Y). Over the last 2 years, UTHR ha...

Shares of MannKind Corporation (NASDAQ: MNKD) , a biotech company that specializes in finding therapies for endocrine and orphan lung diseases, rose 10.4% on Monday. The stock closed at $3.45 on Friday and opened at that price on Monday. A little after 11 a.m., the stock reached its...